NEW YORK, Sept. 21, 2021 /PRNewswire/ -- The economy has shown signs of recovery, but fears related to the pandemic and its new variants remain. Last year, the World Health Organization (WHO) published a list of medical devices required, broken down into several categories including personal protective equipment (PPE), medical equipment, medical consumables, single use devices, laboratory and test-related devices. PPE includes items such as protective clothing, helmets, gloves, face shields, goggles, facemasks and/or respirators. When used properly, PPE acts as a barrier between infectious materials such as viral and bacterial contaminants and your skin, mouth, nose or eyes. The utilization of personal protective equipment (PPE) by the public has helped prevent even higher numbers of infected. Some PPEs are even reviewed by the FDA before they can be legally sold in the United States, and the manufacturers have to show they meet specific criteria for performance, labeling, and intended use to demonstrate substantial equivalence. The global personal protective equipment (PPE) market was valued at USD 52.7 Billion in 2019 and is expected to reach USD 92.5 Billion by 2025 while growing at a CAGR of 8.7% during the period of 2020-2025, according to VynZ Research. OPTEC International, Inc. (OTC: OPTI), Alpha Pro Tech, Ltd. (NYSE: APT), NanoViricides, Inc. (NYSE: NNVC), Chembio Diagnostics, Inc. (NASDAQ: CEMI), Senseonics Holdings, Inc. (NYSE: SENS)
As the pandemic has changed the way we live, disinfectant products have taken on a greater importance. Overall, the high prevalence of Hospital-Acquired Infections (HAIs), awareness about home hygiene and the need for disinfection, as well as the increasing use of endoscope reprocess and surgical units across the globe are anticipated to propel product demand even further. The more traditional disinfectants, which use chemicals to achieve their goals, often include undesirable toxic properties. For example, sodium hypochlorite is an effective treatment against blood-borne pathogens but is also highly corrosive and is a respiratory irritant, which makes it dangerous to cleaning personnel and building occupants, damaging to many surfaces, and toxic when released into the environment.
OPTEC International, Inc. (OTC: OPTI) just announced breaking news regarding the, "company's subsidiary Z2O territories report Period Ending September 19th, 2021.
The company launched the Z2O pilot program earlier this year in Austin Texas, the results of the "Uber" of cleaning services app and service providers was accepted extremely well and continues to gain momentum and growth.
As promised, the Z2O network soft launch was initiated in San Diego and Miami, alongside expanding the existing operations in Austin, Texas. The initial beta testing results for the period 9/08/21 to 9/19/21 have shown a total of $699,404, and the volume of the break down per location indicated that the volume was in Austin $349.330, the volume in Miami was $175,266 and in San Diego was $174,808.
The results of this beta testing proved to have a huge success. The software and the hardware of the Z2O system withstood this volume and no downtime in the logs. Now that the beta results are in, the company plans on having aggressive expansion plans in the U.S. and in the European nations. The European version is being worked on by the engineers and coming along with a lot of positives.
The Z2O users are asking Z2O for additional "uber" type services other than cleaning, and these services range from home repair projects, plumbing services, electrical services, Pet sitting services, senior care services, and babysitting services. We are looking into all of these opportunities to meet Z2O users' needs and request, to provide them the services they are looking for while maintaining a high level of service delivery with the focus on customer satisfaction.
The company will be announcing additional territory launches throughout the rest of the year."
Alpha Pro Tech, Ltd. (NYSE: APT) together with its subsidiaries, develops, manufactures, and markets a range of disposable protective apparel, infection control, and building supply products in the United States and internationally. Last month the Company reported financial results for the three and six months ended June 30, 2021. Lloyd Hoffman, President and Chief Executive Officer of Alpha Pro Tech, commented, "Through the second quarter, we witnessed the softening in demand for our N-95 particulate respirator face mask and face shield sales, consistent with our guidance provided in our first quarter earnings release. Sales for these products declined to be more in line with pre-pandemic quarterly levels and we currently expect similar trends going forward. There is a potential for mask sales to increase again as a result of the recent increased spread of Covid-19, primarily due to the Delta variant. However, due to the inherent uncertainty of the unprecedented and rapidly evolving situation, we are unable to predict with any certainty the likelihood of this on our future operations."
NanoViricides, Inc. (NYSE: NNVC) announced last week that it has completed the process of licensing the human Coronavirus field for drug development and commercialization from TheraCour Pharma, Inc. ("TheraCour"). The Company executed a license agreement for the field comprising anti-viral treatments for coronavirus derived human infections with TheraCour Pharma, Inc. on September 8, 2021 (the "Agreement"). NanoViricides is developing oral and pediatric drugs to fight COVID-19 designed to be effective against most variants. The licensed field includes antiviral drugs to treat SARS-CoV-2 and its variants that cause the COVID-19 disease resulting in a global pandemic that continues to rage through the world, wave after wave, as new variants develop and take hold. There was no upfront cash payment for the license and the compensation terms were generally consistent with prior licenses, and are summarized further below. NanoViricides is currently working on taking its two COVID-19 lead drug candidates, namely, NV-CoV-2- and NV-CoV-2-R, into human clinical trials. The Company believes that the essential preclinical work is substantially complete for taking these drugs into human evaluation.
Chembio Diagnostics, Inc. (NASDAQ: CEMI) reported last month its launch of commercial distribution of an FDA Emergency Use Authorized, patent pending, rapid point-of-care COVID-19 antigen test for use in decentralized and traditional testing settings. Product inventory is on-hand and immediately available for shipment to Chembio customers across the United States. The SCoV-2 Ag Detect™ Rapid Test, manufactured by InBios International, Inc., is a rapid immunoassay test authorized for use in laboratories with a CLIA waiver certification. It provides results in 20 minutes from a nasal swab and requires no instrumentation. The test can be used for both patients who are suspected of COVID-19 by their healthcare provider within 5 days of symptom onset and for asymptomatic serial testing. "We are excited about the addition of this differentiated product to our menu of COVID-19 assays," said Charles Caso, Vice President of Sales and Marketing for Chembio. "We are now offering U.S. customers SCoV-2 Ag Detect™, a test for COVID-19 antigens in both symptomatic and asymptomatic populations, as well as Status™ COVID-19/Flu A&B, a product that differentiates flu from COVID-19 using a single nasal swab sample. Our expanded commercial team can now offer testing solutions for CLIA waived settings and work and school settings."
Senseonics Holdings, Inc. (NYSE: SENS) announced last week that the University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio has begun offering the Eversense® CGM System to its Medicare enrollees effective early September, 2021. The recent decision to use the Eversense CGM System in eligible patients with type 1 diabetes or type 2 diabetes on insulin shows the commitment of UHACO to facilitate optimal diabetes management for its enrollees. "We are excited to offer Eversense to our ACO patients with diabetes. Supplying tools for effective glucose management allows us to meet the Standards of Care for patients using insulin as outlined by the American Diabetes Association," said Betul Hatipoglu, M.D., Head of Endocrinology and Diabetes at UHACO. "Eversense offers patients choice amongst continuous glucose monitoring devices. The Eversense CGM system delivers industry leading accuracy, an improved patient experience, and an array of unique features that afford people, especially those in the Medicare population, the opportunity to achieve improved health outcomes."
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.